NCT02743754

Brief Summary

Kidney injury is a serious complication of cardiac surgery that occurs in up to 30% of patients and increases the risk of adverse outcomes. Kidney injury initiates when oxygen supply to the kidney drops below levels that are needed for normal cellular function, causing tissue oxygen deficiency (hypoxia), activation of the inflammatory cascade, and oxidative stress. Together, these events further impair tissue oxygenation, culminating in impaired kidney function due to cellular injury and death. There are no effective therapies for kidney injury after cardiac surgery, but there is evidence that recovery is possible if the processes of injury - i.e., impaired oxygen delivery, increased inflammatory response, and oxidative stress - are ameliorated soon after the onset of injury. Hyperbaric oxygen therapy (HBOT) - which entails the intermittent inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than one absolute atmosphere (\> 760 mmHg) - has been shown to positively affect all of these processes (i.e., to improve tissue oxygenation, reduce inflammation, and reduce oxidative stress). Thus, we hypothesized that HBOT will reduce the severity of kidney injury after cardiac surgery if it is initiated soon after onset of injury. This hypothesis has not been tested in humans, but is supported by animal studies. In this first-in-human, unblinded, controlled pilot trial, 20 adult patients who develop severe kidney injury soon after cardiac surgery will be randomized (after obtaining informed consent from the patient or surrogate) to standard-of-care or early HBOT. Severe kidney injury will be defined as a ≥30% drop in kidney function within 6 hours of surgery (as determined by change in creatinine from before surgery to Intensive Care Unit (ICU) admission). This degree of injury occurs in \~ 2% of patients and is associated with a 12-fold increase in the risk of complete kidney failure (requiring dialysis) or death. Patients will be excluded if they have any relative or absolute contraindications to HBOT (e.g., severe ventricular dysfunction, ventricular assist device, severe respiratory dysfunction, pneumothorax, bronchospasm).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2015

Completed
5 months until next milestone

First Posted

Study publicly available on registry

April 19, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

June 10, 2016

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 7, 2017

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

May 17, 2019

Status Verified

May 1, 2019

Enrollment Period

1.2 years

First QC Date

November 30, 2015

Last Update Submit

May 15, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Feasibility of the intervention

    The proportion of patients qualified but not consented and the proportion of patients completing the study from each group.

    7 days

  • Safety of the intervention as assessed by adverse events

    Adverse events that are related to the intervention.

    7 days

Study Arms (2)

Standard Therapy

PLACEBO COMPARATOR

Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.

Other: Standard therapy

Standard Therapy and hyperbaric oxygen

ACTIVE COMPARATOR

Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).

Other: Standard therapyOther: Hyperbaric Oxygen

Interventions

The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.

Standard TherapyStandard Therapy and hyperbaric oxygen

The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.

Standard Therapy and hyperbaric oxygen

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \> 18 years
  • any cardiac surgery with cardiopulmonary bypass surgery
  • ≥30% drop in kidney function within 6 hours of surgery (determined by change in creatinine from before surgery to ICU admission)

You may not qualify if:

  • Pre-existing renal dysfunction (creatinine \> 177 µmol/L)
  • claustrophobia
  • seizure disorder
  • severe respiratory dysfunction (PaO2/fraction of inspired oxygen (FiO2) ratio \<150 on 100% O2 and Peep of 10)
  • active asthma or bronchospasm
  • severe chronic obstructive pulmonary disease
  • history of spontaneous pneumothorax or untreated pneumothorax
  • congestive heart failure with left ventricular ejection fraction \< 30%
  • evidence of ongoing myocardial ischemia
  • presence of ventricular assist device or intra-aortic balloon pump
  • chronic sinusitis
  • chronic/ acute otitis media or major ear drum trauma
  • current treatment with bleomycin, cisplatin, doxorubicin and disulfiram

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto General Hopsital University Health Network

Toronto, Ontario, M5G 2C4, Canada

Location

MeSH Terms

Conditions

Acute Kidney Injury

Interventions

Standard of CareHyperbaric Oxygenation

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationOxygen Inhalation TherapyRespiratory TherapyTherapeutics

Study Officials

  • Keyvan Karkouti, MD

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2015

First Posted

April 19, 2016

Study Start

June 10, 2016

Primary Completion

September 7, 2017

Study Completion

May 1, 2019

Last Updated

May 17, 2019

Record last verified: 2019-05

Locations